Skip to main content

Table 1  Demographics details, clinical data, and laboratory data. Results are reported as n (%) or median (IQR)

From: Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy

  Death at 1 year Total (N = 153)
No (N = 67) Yes (N = 86)
Age (years) 60.00 (38.50–68.50) 63.00 (50.25–70.00) 61 (46–69)
Male 45 (67.2) 60 (69.8) 105 (69)
G6PD deficiency 7 (10.4) 2 (2.3) 9 (6)
Underlying malignancy    
 Solid cancer 0 (0) 2 (2.3) 2 (1)
 Leukemia 23 (34.3) 29 (33.7) 52 (34)
 Non-Hodgkin lymphoma 38 (56.7) 52 (60.5) 90 (59)
 Multiple myeloma 2 (3.0) 0 (0) 2 (1%)
 Other 4 (6.0) 3 (3.5) 7 (5%)
 Spontaneous TLS 34 (50.7) 56 (65.1) 90 (59)
Risk of TLS    
 Low risk 9 (13.4) 15 (17.4) 24 (16)
 Intermediate risk 5 (7.5) 4 (4.7) 9 (6)
 High risk 53 (79.1) 67 (77.9) 120 (78)
Cardiovascular risk    
 Chronic hypertension 19 (28.4) 27 (31.4) 46 (30.1)
 Diabetes 7 (10.4) 12 (14.0) 19 (12.4)
 Cardiovascular event 5 (7.5) 10 (11.6) 15 (9.8)
 Chronic kidney disease 6 (9.2) 4 (4.7) 10 (6.6)
 HIV positive status 7 (10.4) 19 (22.1) 26 (17)
 SOFA score 5.00 (3.00–8.00) 7.50 (5.00–12.00) 6.5 (4–9)
 Vasopressors 1 (1.5) 21 (36) 24 (16)
 Mechanical ventilation 5 (7.5) 29 (33.7) 34 (22.2)
 Rasburicase use 54 (80.6) 60 (69.8) 114 (75)
Laboratory data at admission    
 Kalemia, mEq/L 4.60 (4.00–5.00) 4.30 (3.90–5.00) 4.3 (3.9–5.0)
 Phosphatemia, mg/dL 4.59 (3.61–6.08) 4.19 (3.08–5.94) 4.45 (3.41–5.88)
 Calcemia, mg/dL 8.94 (7.90–9.50) 8.50 (7.84–9.45) 8.80 (8–9.60)
 Uricemia, mg/dL 8.96 (5.64–13.10) 7.49 (5.12–12.16) 8.46 (5.23–12.41)
 LDH, UI/L 2700 (1544–5168) 2855 (1544–5263) 2819 (1533–5169)
Delay admission-chemotherapy (days) 1 (0–7) 4 (0.5–12) 2.5 (0–11)
ICU mortality 0 (0) 27 (31.4) 27 (18)
One-year remission 54 (80.6) 0 (0.0) 54 (35.3)
  1. G6PD glucose 6 phosphate dehydrogenase, TLS tumor lysis syndrome, HIV human immunodeficiency virus, LDH lactate dehydrogenase, ICU intensive care unit